Payment overview · 2025
General Payments
$146.40
8 reported records · 5 companies
Healthcare provider profile · identity verified
Benjamin Bradley, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OKMULGEE, OK · NPI 1730518788
Verified facts
What the public records show
CMS Open Payments records show Benjamin Bradley, CNP received $146.40 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.80 | 27.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.86 | 25.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.69 | 19.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.63 | 15.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.42 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.40 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 273 | 64 |
| Losartan Potassium | Losartan Potassium | 239 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 207 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 50 |
| Lisinopril | Lisinopril | 174 | 47 |
| Omeprazole | Omeprazole | 173 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 30 |
| Trazodone Hcl | Trazodone Hcl | 122 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 25 |
| Alprazolam | Alprazolam | 111 | 20 |
| Furosemide | Furosemide | 110 | 29 |
| Mounjaro | Tirzepatide | 103 | 21 |
| Metformin Hcl Er | Metformin Hcl | 97 | 26 |
| Potassium Chloride | Potassium Chloride | 92 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 19 |
| Carvedilol | Carvedilol | 85 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 19 |
| Meloxicam | Meloxicam | 71 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 24 |
| Sertraline Hcl | Sertraline Hcl | 65 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 18 |
| Metformin Hcl | Metformin Hcl | 56 | 18 |
| Ondansetron Odt | Ondansetron | 50 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Terazosin Hcl | Terazosin Hcl | 44 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Jardiance | Empagliflozin | 40 | 12 |
| Celecoxib | Celecoxib | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Atenolol | Atenolol | 38 | 12 |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 35 |
| Eliquis | Apixaban | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 14 |
| Allopurinol | Allopurinol | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 15 |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 21 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Linzess | Linaclotide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.40 · 8 records | PFIZER INC. | AIRSUPRA, JARDIANCE, PAXLOVID, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error